Neuralstem shows positive results in study on Alzheimer's disease

KUALA LUMPUR, July 24 (Bernama) -- Neuralstem Inc -- a biopharmaceutical company developing novel treatments for nervous system diseases -- announced some positive results in the treatment of Alzheimer’s disease.



This was disclosed in the presentation of data at the Alzheimer's Association International Conference in Chicago, Illinois.



The presentation demonstrated that oral administration of NSI-189 in a mouse model of Alzheimer’s disease (AD) leads to a significant amelioration and/or improvement in cognition measures and anxiety, a statement said.



Key findings from the study shows that treatment with NSI-189 significantly improved the learning ability measured by a simple task and improved performance on a test of short term memory (Novel Object Recognition).



The results also improved motor learning of AD mice as measured by performance on a Rotarod test and decreased anxiety levels in both AD mice and control mice as measured by an open field test.



“Data from this preclinical study suggest that NSI-189 may be able to mitigate or reverse the cognitive impact of Alzheimer’s disease,” said associate professor in the Department of Pathology at UC San Diego School of Medicine, Dr. Corinne Jolivalt.



The study carried out by Dr. Jolivalt’s laboratory at the University of California, San Diego involved the oral administration of NSI-189 to mice harboring gene changes that recreate symptoms of familial Alzheimer’s disease.



-- BERNAMA